Recent Medicine press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

 

[PRESSWIRE] Austria - 04.07.22 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

1

A group of 18,000 blood donation contributes to stability of blood supply in South Korea

 

[PRESSWIRE] Asia - 03.05.22 -- In South Korea, in cooperation with Heavenly Culture, World Peace and Restoration of Light (HWPL), 18,000 members of Shincheonji Church of Jesus and HWPL participated in blood donation for two weeks from April 18th. This number was recorded as the largest group blood donation in the country.

1

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

 

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

1

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC

 

[PRESSWIRE] Vienna - 23rd February 2022 -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

1

Using Smart Sensors and Cloud-based Analytics, Canary’s 20-minute Handheld COVID-19 Saliva-based Molecular Test with PCR Quality Results Achieves CE Mark

• Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants
• Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening
• A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance

1

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant

 

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing

 

[PRESSWIRE] Austria - 04 May, 2021 -- CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

 

[PRESSWIRE] Vienna, Austria - 17 February, 2021 -- In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.

Stragen Announces First Subject Enrolled in Phase IIa Clinical Trial of its non-opioid analgesic STR-324

The Stragen group announced today the enrollment of the first subject to participate in a Phase IIa study of STR-324...

1

Necenti Labs pioneers COVID test that can let employers get staff back to work

[PRESSWIRE] Madrid, Spain - 25 January, 2021 -- An innovative new technology from Necenti Labs offers 96% accuracy for COVID-19 detection before infection with deep data to give companies and individuals the power of knowledge to battle lockdown.